|
Adis LMS Drug Alerts is based on the Adis Literature Monitoring
and Evaluation Service and presents highly structured evaluations
(summaries) of key papers. In addition, bibliographic records are
included in the database for all other papers sourced by Adis that
are not evaluated.
Key papers are selected and evaluated by Adis editorial specialists
and are presented in a structured and consistent format to provide
a clear definition of the study and results. Drug and regimes,
results and side effects are presented in easy-to-read tables
Adis LMS Drug Alerts also provides an evaluation score for clinical
trials as an independent guide to the quality of the trial, design
and reporting.
Use AC89 to answer questions like:
- what pattern of cardiovascular side effects is beginning to emerge
with renin inhibitors?
- what review articles have been published on ACE-inhibitors over
the past five years?
- have there been any fair to excellent trials on the therapeutic
use of tryptophan?
- what cardiovascular disorders are induced by salbutamol?
Sources:
Over 1600 international medical and biomedical journals on drugs,
drug therapy, pharmacoeconomics and adverse drug experiences are
monitored.
AC89 replaces AALR. Adis International have relaunched LMS Drug
Alerts with Adis Clinical Trials Insight which is available in ACTI,
AC00 and ACZZ. These files are in a different format to AC89 -
refer to the ACTI database guide in BASE for information on how to
search these files - search as BASE- ACTI.
Accession number & update
800008450 20010301.
Title
Preliminary results of a wheat-free and milk-free diet in rheumatoid
arthritis.
Source
Presse-Medicale (Presse-Med). 18: 1931-1932, 25 Nov 1989.
Author(s)
Seignalet-J, Pauthe-C, Reynier-J, Moens-P, Simon-L.
Author affiliation
Hopital Saint-E; loi, Montpellier, France; Hopital Lapeyronie,
Montpellier, France.
Adis title
Rheumatoid arthritis: management.
Influence of a wheat- and milk-free diet.
Adis source
Adis LMS: Rheumatic Disease (Summary): Alert no. 4, 1990.
Text
1 OF 6
Purpose:
Previous studies assessing the effectiveness of exclusion diets in
rheumatoid arthritis (RA) have shown little success when either milk
or wheat were maintained. This study assessed the efficacy of a
wheat- and milk-free diet in patients with RA who had been
unsuccessfully treated with conventional drug therapy.
2 OF 6
Author comments:
The proportion of successes on the diet appeared to exceed the
placebo effect that has been previously reported. Recurrence of
symptoms after discontinution of the diet, and remission after its
reinstitution suggest that the exclusion of wheat and milk must be
maintained for life.
3 OF 6
Study details:
Design: open
Control: baseline comparison
Subjects:
Type: patients
No: 24
Groups: 1
4 OF 6
Characteristics:
all patients met the ARA criteria for RA; duration and severity of RA
was variable, but the disease was active in all patients.
5 OF 6
Drug table:
--------------------------------------------------------------------
Drug Duration
--------------------------------------------------------------------
Milk-and wheat-free diet 3-18 months
--------------------------------------------------------------------
6 OF 6
Results table:
--------------------------------------------------------------------
After <= 18 months
--------------------------------------------------------------------
Patients showing no improvement 5
Patients showing a clear improvement 19
Patients in remission 6
Proportion of successes 19/24
--------------------------------------------------------------------
Improvements were seen in all efficacy assessment parameters, except
ESR where changes were not constant.
Study type
Case report.
Descriptors
Diet.
Rheumatoid-arthritis, management.
Language
French (FR).
Publication date
25 November 1989 (19891125).
Adis summary
Yes.
Occurrences
Publication date (1)
Length
1,536 Characters, approximately 1 PC screen.
SAMPLE BIBLIOGRAPHIC DOCUMENT
Accession number & update
800564353 19891001.
Title
Alternating combination chemotherapy (VMCP/VBAP) is not superior to
melphalan/prednisone in the treatment of multiple myeloma patients
stage III - A randomized study from MGCS.
Source
European-Journal-of-Haematology (Eur-J-Haematol). 43: 54-62, Jul
1989.
Author(s)
Osterborg-A, Ahre-A, Bjorkholm-M, et-al.
Adis source
Adis LMS: Cancer Chemotherapy (Index only): Alert no. 2, 1990.
Study type
Clinical study.
Descriptors
Melphalan, therapeutic-use.
Multiple-myeloma, treatment.
Prednisone, therapeutic-use.
Language
English (EN).
Publication date
01 July 1989 (19890701).
Adis summary
No.
Occurrences
Publication date (1)
Adis summary (1)
Length
1,690 Characters, approximately 1 PC screen.
Label/description Example
AN Accession number 1_: 800008450.AN.
& update - see Limit options -
TI Title 2_: DIET WITH ARTHRITIS.TI.
SO Source 3_: PRESSE-MEDICALE.SO.
or 4_: PRESSE ADJ MEDICALE.SO.
or 5_: PRESSE-MED.SO.
AU Author(s) 6_: SEIGNALET-J$.AU.
or 7_: SEIGNALET.AU.
IN Author affiliation 8_: LAPEYRONIE WITH MONTPELLIER.IN.
AT Adis title 9_: WHEAT AJD FREE.AT.
AS Adis source 10_: RHEUMATIC ADJ DISEASE.AS.
EV Evaluation 11_: 83.EV.
TX Text 12_: EXCLUSION ADJ DIET$1.TX.
SE Side effects 13_: NAUSEA.SE.
OT Outcome 14_: RECOVERY.OT.
TY Study type 15_: CASE.TY.
DE Descriptors 16_: RHEUMATOID-ARTHRITIS.DE.
or 17_: RHEUMATOID ADJ ARTHRITIS DE.
LG Language 18_: LG=EN
DT Publication date 19_: DT=19891125
Publication month 20_: YM=198911
Publication year 21_: YR=1989
SU Adis summary 22_: SU=YES
LE Length - Display only -.
1_: ARTHRITIS.TX.
EV Evaluation score 2_: ..L 1 EV>50
PA Number of patients 3_: 1 NOT PA=NA
4_: ..L 3 PA<20
GR Number of groups 5_: ..L 1 GR=5
DATE Publication date 6_: ..L 1 DATE<19891231
YEAR Publication year 7_: ..L 1 YEAR WL 1983,1985
UDATE Update date 8_: ..L 1 UDATE>19881123
UMONTH Update month 9_: ..L 1 UMONTH>198901.
By paragraph - title, text _: ..P TI, TX(1,5) 1-4
SHORT AN TI SO AU IN AS TY LG DT SU OC LE
MEDIUM AN TI SO AU IN AT AS EV TX TY LG DT SU OC
LONG AN TI SO AU IN AT AS EV TX SE OT TY DE LG DT SU OC
HITS All paragraphs where search terms occur
KWIC Context of search terms in TX paragraph
ALL AN TI SO AU IN AT AS EV TX SE OT TY DE LG DT SU OC LE
FREE AN TI DT SU OC LE
_: ..P SHORT 1,8,10.
Terminology:
Generic drug names (INN/Adis preferred terms) are used throughout
Adis databases. When an INN or other non-proprietary name has not
been established, the research code, chemical name or other generic
name is used.
Spelling:
US English is used up to the end of 1989. For a comprehensive search
covering both periods, set Medword to on.
AT - Adis Title:
This is the headline for the printed summary; it is NOT the same as
the TI field. If the document is a summary of a review article, the
number of references cited by the original article is indicated.
Some original papers may generate two documents where distinct
studies are reported in which case the wording, e.g. '(Summary in 2
parts: part A)' will appear. Documents dependent on another record
will commonly have the same Adis Title with the annotation
'(Follow-up comment)'.
EV - Adis Evaluation:
This is the score assigned to Adis to therapeutic trial reports. It
is based on the adequacy of the data provided by the report and is a
cumulation of the individual scores awarded to elements of the study
design and conduct. Scores are categorised as:
86 - 100 Excellent trial
71 - 85 Good to very good
50 - 70 Fair trial
less than 50 Unacceptable trial or results require confirmation
by a better designed study.
MEDWORD should be used in AC89. ..RANK and ..MAP are available in the AN and
TI paragraphs.
ADIS DATA INFORMATION BV
Database copyrighted by Adis Data Information BV. Data may not be
duplicated in hard copy or machine-readable format without
written permission of Adis Data Information BV.
If data is to be distributed under The Dialog Corporation's
Redistribution and Archiving (ERA) policy, distribution
is restricted to the company and geographical boundaries of the
country where the data was downloaded. Data which has been
downloaded under this provision may not be sold or resold to a third
party outside the company organization.
Back to the Datasheet Index Page
© 2008 Dialog DataStar
|